Gel drug-loading material and preparation method and application thereof
A cross-linked polymer of gelatin and modified cyclodextrin addresses the poor sustained-release issue in gelatin-based materials, providing enhanced drug delivery and mechanical strength for applications like ocular drainage tubes.
Patent Information
- Application Number
- CN202411204293.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-06
AI Technical Summary
Gelatin-based drug-carrying materials exhibit poor sustained-release control, limiting their effectiveness in drug delivery systems.
A cross-linked polymer of gelatin and modified cyclodextrin, incorporating cross-linking groups such as amide, imine, ester, and ether groups, enhances drug packaging and sustained-release properties while improving mechanical strength.
The gel drug-carrying material achieves controlled drug release and maintains mechanical integrity, suitable for applications like ocular drainage tubes and sustained-release drug delivery plugs.
Smart Images

Figure CN119074640A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of medical biomaterial technology, and in particular to a gel drug-carrying material and a preparation method and application thereof. Background Art
[0002] Drug-carrying materials play an important role in drug delivery systems as carriers of drugs. The base material of drug-carrying materials is generally a biodegradable material with biocompatibility, and the slow degradation of the biodegradable material can achieve the slow release of the drug.
[0003] Gelatin is widely used in the preparation of drug-carrying materials due to its good biocompatibility and superior degradation performance. However, the drug sustained-release control effect of gelatin is not ideal, resulting in many limitations in its use. Summary of the invention
[0004] In view of the problems existing in the prior art, the embodiments of the present application provide a gel drug-carrying material, which can improve the problem of poor sustained-release effect of gelatin drugs.
[0005] In a first aspect, an embodiment of the present application provides a gel drug-carrying material, which includes a cross-linked polymer of gelatin and modified cyclodextrin, wherein the gelatin and the modified cyclodextrin are cross-linked and polymerized via a cross-linking group, and the cross-linking group includes one or more of an amide group, an imine group, an ester group and an ether group.
[0006] In the embodiments of the present application, the gel material obtained by cross-linking and polymerizing modified cyclodextrin and gelatin through specific cross-linking groups can make the gel drug-carrying material have good drug packaging and sustained-release effects by utilizing the unique structural characteristics of cyclodextrin. At the same time, the mechanical properties of gelatin can be further improved by cross-linking and polymerizing modified cyclodextrin and gelatin, so that the gel drug-carrying material has both high mechanical strength and drug sustained-release properties.
[0007] In some embodiments, the modified groups of the modified cyclodextrin include one or more of an amino group, a carboxyl group, and an aldehyde group.
[0008] In some embodiments, the content of the modified group in the modified cyclodextrin is 0.88 mmol / g to 4.40 mmol / g.
[0009] In some embodiments, the modified cyclodextrin includes one or more of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and their respective derivatives modified by a modifying group.
[0010] In some embodiments, the modified cyclodextrin includes one or more of mono-(6-amino-6-deoxy)-β-cyclodextrin, 3A-amino-3A-deoxy-(2AS, 3AS)-β-cyclodextrin, 6-perdeoxy-6-per(2-carboxyethyl)-γ-cyclodextrin, and mono-(6-aldehyde-6-deoxy)-β-cyclodextrin.
[0011] In some embodiments, the mass content of modified cyclodextrin in the gel drug-carrying material is 1% to 15%.
[0012] In some embodiments, the drug-carrying gel material has a porous structure with a porosity of 50% to 70%.
[0013] In a second aspect, the present invention provides a method for preparing a gel drug-carrying material, comprising the following steps:
[0014] Modified cyclodextrin and gelatin are provided separately;
[0015] The modified cyclodextrin and the gelatin are cross-linked and polymerized via a cross-linking group to obtain the gel drug-carrying material, wherein the cross-linking group includes one or more of an amide group, an imine group, an ester group and an ether group.
[0016] In some embodiments, the cross-linking polymerization of the modified cyclodextrin and the gelatin via a cross-linking group comprises:
[0017] The modified cyclodextrin is mixed with gelatin and molded to obtain a prepolymer;
[0018] The prepolymer is mixed with a cross-linking agent to initiate polymerization of the prepolymer to obtain the gel drug-carrying material.
[0019] In some embodiments, the mixing and molding of the modified cyclodextrin and gelatin to obtain a prepolymer comprises:
[0020] dispersing the modified cyclodextrin in a dispersant to obtain a modified cyclodextrin dispersion;
[0021] adding the gelatin into the cyclodextrin dispersion to mix the modified cyclodextrin with the gelatin to obtain a mixed solution;
[0022] The mixed liquid is molded in a mold to obtain the prepolymer.
[0023] In some embodiments, the dispersant includes one or both of PBS solution and deionized water.
[0024] In some embodiments, the mass content of modified cyclodextrin in the dispersion is 0.25 g / mL to 2.5 g / mL.
[0025] In some embodiments, the mass ratio of the modified cyclodextrin to the gelatin is 1:(5.67-99).
[0026] In some embodiments, the mixing temperature of the modified cyclodextrin and the gelatin is 45°C to 60°C.
[0027] In some embodiments, the mixing of the prepolymer with a cross-linking agent to initiate polymerization of the prepolymer to obtain the gel drug-carrying material comprises:
[0028] mixing the cross-linking agent with a solvent to obtain a cross-linking agent solution;
[0029] adding the prepolymer into the crosslinking agent solution, so that the crosslinking agent initiates the polymerization of the prepolymer to obtain a polymer;
[0030] The polymer is washed with water and then dried to obtain the gel drug-carrying material.
[0031] In some embodiments, the cross-linking agent includes one or more of glutaraldehyde, 1-ethyl-(3-dimethylaminopropyl)carbodiimide, N-hydroxysuccinimide, oxidized dextran, epoxy polyethylene glycol, epoxy acrylic acid, acrylic anhydride, and polyethylene glycol diglycidyl ether.
[0032] In some embodiments, the solvent includes one or more of methanol, ethanol, acetonitrile, and tetrahydrofuran.
[0033] In some embodiments, the mass content of the cross-linking agent in the cross-linking agent solution is 0.005 g / mL to 0.5 g / mL.
[0034] In some embodiments, the mass ratio of the cross-linking agent to the gelatin is 1:(0.01-0.1).
[0035] In some embodiments, the modified cyclodextrin includes a drug-loaded cyclodextrin.
[0036] According to the embodiments of the present application, the preparation method of the second aspect of the present application can be used to prepare the gel drug-loaded material of the first aspect of the present application.
[0037] In a third aspect, the embodiments of the present application provide the use of the gel drug-loaded material according to the embodiments of the first aspect of the present application or the gel drug-loaded material obtained by the preparation method according to the embodiments of the second aspect of the present application in a drug-loaded sustained-release system.
[0038] In a fourth aspect, an embodiment of the present application provides a drug-loaded sustained-release system, comprising a drug-loaded matrix and a drug loaded on the drug-loaded matrix, wherein the drug-loaded matrix comprises the gel drug-loaded material of the first aspect embodiment of the present application or the gel drug-loaded material obtained by the preparation method of the second aspect embodiment of the present application, and the gel drug-loaded material is loaded with a drug.
[0039] In some embodiments, the drug loading amount of the drug-loaded sustained-release system is 700 μg / mg to 1000 μg / mg.
[0040] In some embodiments, the drug includes one or more of an anti-proliferative drug, an ocular hypotensive drug, an anti-inflammatory drug, an antibacterial drug, an anti-allergic drug, and an eye lubricating drug.
[0041] In some embodiments, the drug-loaded sustained-release system includes one or more of an ocular drainage tube, a sustained-release drug delivery plug, and a sustained-release corneal contact lens. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] In order to more clearly illustrate the technical solution of the embodiments of the present application, the following is a brief introduction to the drawings required for use in the embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.
[0043] Figure 1 It is the nuclear magnetic hydrogen spectrum of the gel drug-carrying material in some embodiments of the present application.
[0044] Figure 2 This is the drug release curve of the gel drug-carrying material in some embodiments of the present application.
[0045] Figure 3 A diagram showing the results of an anti-scarring cell experiment using a drug-loaded gel material prepared in some embodiments of the present application. DETAILED DESCRIPTION
[0046] The features and exemplary embodiments of various aspects of the present application will be described in detail below. In the detailed description below, many specific details are proposed to provide a comprehensive understanding of the present application. However, it is obvious to those skilled in the art that the present application can be implemented without the need for some of these specific details. The following description of the embodiments is only to provide a better understanding of the present application by illustrating examples of the present application. In the accompanying drawings and the following description, at least some of the known structures and technologies are not shown to avoid unnecessary ambiguity in the present application; and, for clarity, the size of some structures may be exaggerated. In addition, the features, structures or characteristics described below may be combined in one or more embodiments in any suitable manner.
[0047] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish an entity or operation from another entity or operation, and do not necessarily require or imply that there is any such actual relationship or order between these entities or operations. In the description of the present application, it should be noted that, unless otherwise specified, the meaning of "multiple" is more than two. Moreover, the term "include", "comprise" or any other variant thereof is intended to cover non-exclusive inclusion, so that the process, method, article or equipment including a series of elements not only include those elements, but also include other elements not clearly listed, or also include elements inherent to such process, method, article or equipment. In the absence of more restrictions, the elements limited by the sentence "include..." do not exclude the existence of other identical elements in the process, method, article or equipment including the elements.
[0048] Gel drug loading material
[0049] An embodiment of the first aspect of the present application provides a gel drug-carrying material, which includes a cross-linked polymer of gelatin and modified cyclodextrin, wherein the gelatin and the modified cyclodextrin are cross-linked and polymerized via a cross-linking group, and the cross-linking group includes one or more of an amide group, an imine group, an ester group and an ether group.
[0050] Gelatin has good biocompatibility and biodegradability, and cyclodextrin is a cyclic oligosaccharide composed of glucose, which is non-toxic, harmless, has no side effects, and can be absorbed by the human body. Cyclodextrin has a slightly conical hollow cylindrical three-dimensional structure. This conical cylindrical structure can well accommodate various shell molecules, so it can be used as a carrier medium for drugs, so that the effective ingredients of the drug are encapsulated in the cylindrical cavity of cyclodextrin, so that the drug is slowly released, the drug efficacy is improved, and the drug release period is extended. In the embodiment of the present application, the gel material obtained by cross-linking and polymerizing modified cyclodextrin and gelatin through specific cross-linking groups can make the gel drug-carrying material have good drug packaging and sustained-release effects by utilizing the unique structural characteristics of cyclodextrin. At the same time, the mechanical properties of gelatin can be further improved by cross-linking and polymerization of modified cyclodextrin and gelatin, so that the gel drug-carrying material has both high mechanical strength and drug sustained-release properties.
[0051] Figure 1 The nuclear magnetic hydrogen spectra of the gel drug-carrying material, gelatin and modified cyclodextrin in some embodiments of the present application are shown. It can be seen that the modified cyclodextrin and gelatin are effectively cross-linked through the action of the cross-linking groups.
[0052] In some embodiments, the modified group of the modified cyclodextrin may include one or more of an amino group, a carboxyl group, and an aldehyde group.
[0053] By modifying cyclodextrin, modified groups including amino, carboxyl and aldehyde groups can be introduced into cyclodextrin, and these modified groups can react with active groups on gelatin such as amino, carboxyl, hydroxyl, ether, etc. to undergo cross-linking polymerization. By introducing amino, carboxyl or aldehyde groups into cyclodextrin, amino cyclodextrin, carboxylated cyclodextrin and oxidized cyclodextrin can be obtained respectively.
[0054] In some embodiments, the content of the modified groups in the modified cyclodextrin can be 0.88 mmol / g to 4.40 mmol / g. The content of the modified groups in the modified cyclodextrin within the above range is conducive to cross-linking polymerization of the modified cyclodextrin and gelatin to form a structurally stable gel drug-carrying material.
[0055] In some embodiments, the cyclodextrin may include one or more of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and their respective derivatives. The modified cyclodextrin may be modified for any one or more of the above cyclodextrins. For example, the modified cyclodextrin may include one or more of amino α-cyclodextrin, amino β-cyclodextrin, amino γ-cyclodextrin, carboxylated α-cyclodextrin, carboxylated β-cyclodextrin, carboxylated γ-cyclodextrin, oxidized α-cyclodextrin, oxidized β-cyclodextrin, and oxidized γ-cyclodextrin.
[0056] Exemplarily, the modified cyclodextrin may include one or more of mono-(6-amino-6-deoxy)-β-cyclodextrin, 3A-amino-3A-deoxy-(2AS,3AS)-β-cyclodextrin, 6-perdeoxy-6-per(2-carboxyethyl)-γ-cyclodextrin, and mono-(6-aldehyde-6-deoxy)-β-cyclodextrin.
[0057] In some embodiments, the mass content of modified cyclodextrin in the gel drug-carrying material can be 1% to 15%. Exemplarily, the mass content of modified cyclodextrin in the gel drug-carrying material can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, or a range composed of any of the above values. Optionally, the mass content of modified cyclodextrin in the gel drug-carrying material is 3% to 12%. More optionally, the mass content of modified cyclodextrin in the gel drug-carrying material is 5% to 10%.
[0058] In the present application, the mass content of modified cyclodextrin in the gel drug-carrying material refers to the mass proportion of the modified cyclodextrin part in the gel drug-carrying material formed by cross-linking polymerization of modified cyclodextrin and gelatin. By controlling the proportion of the modified cyclodextrin part in the gel drug-carrying material within the above range, the gel material can have a suitable drug sustained-release effect while having good mechanical strength. Within this range, by adjusting the content of modified cyclodextrin, the drug loading and drug release rate of the gel drug-carrying material can be further regulated to meet the requirements of different types of drugs for release rate.
[0059] In some embodiments, the drug-carrying gel material has a porous structure, and its porosity can be 50% to 70%. Exemplarily, the porosity of the drug-carrying gel material can be 50%, 51%, 52%, 53%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, or a range consisting of any of the above values.
[0060] In the present application, porosity refers to the ratio of the pore volume in the gel drug-loaded material to the total volume of the gel drug-loaded material in the natural state, which can be detected by instruments and methods known in the art, for example, by gas adsorption method (BET method).
[0061] In the embodiments of the present application, by limiting the porosity of the gel drug-loaded material to the above range, the gel drug-loaded material can have a suitable drug loading amount and drug release rate, while the gel drug-loaded material can maintain good mechanical strength.
[0062] Preparation method of gel drug-carrying material
[0063] The second aspect of the present application provides a method for preparing a gel drug-carrying material, comprising the following steps:
[0064] S100, providing modified cyclodextrin and gelatin, respectively;
[0065] S200, cross-linking and polymerizing the modified cyclodextrin and gelatin via cross-linking groups to obtain a gel drug-carrying material. The cross-linking groups may include one or more of amide groups, imine groups, ester groups, and ether groups.
[0066] In the examples of the present application, both the modified cyclodextrin and gelatin can be commercially available. The gelatin can be commercially available type A gelatin or type B gelatin.
[0067] In some embodiments, step S200 may include the following steps S210 to S250:
[0068] S210, dispersing the modified cyclodextrin in a dispersant, and fully stirring and dissolving to obtain a cyclodextrin dispersion.
[0069] In some embodiments, the dispersant may include one or both of phosphate buffered saline (PBS), deionized water.
[0070] In some embodiments, the mass concentration of cyclodextrin in the cyclodextrin dispersion can be 0.25 g / mL to 2.5 g / mL. Exemplarily, the mass concentration of cyclodextrin in the cyclodextrin dispersion can be 0.25 g / mL, 0.30 g / mL, 0.35 g / mL, 0.40 g / mL, 0.45 g / mL, 0.50 g / mL, 0.55 g / mL, 0.60 g / mL, 0.65 g / mL, 0.70 g / mL, 0.75 g / mL, 0.80 g / mL, 0.85 g / mL, 0.90 g / mL, 0.95 g / mL, 1.0 g / mL, 1.1 g / mL, 1.2 g / mL, 1.3 g / mL, 1.4 g / mL, 1.5 g / mL, 1.6 g / mL, 1.7 g / mL, 1.8 g / mL, 1.9 g / mL, 2.0 g / mL, 2.1 g / mL, 2.2 g / mL, 2.3 g / mL, 2.4 g / mL, 2.5 g / mL, or a range consisting of any of the above values.
[0071] Optionally, the mass concentration of modified cyclodextrin in the modified cyclodextrin dispersion may be 0.5 g / mL to 2.2 g / mL; more optionally, the mass concentration of cyclodextrin in the cyclodextrin dispersion may be 0.8 g / mL to 2.0 g / mL.
[0072] In some embodiments, the modified cyclodextrin can be a modified cyclodextrin loaded with a drug. The drug is pre-loaded on the modified cyclodextrin and then cross-linked with gelatin, so that the drug is encapsulated on the gel drug-carrying material. The type of drug can be selected according to specific needs.
[0073] S220, adding gelatin to the cyclodextrin dispersion, stirring and dissolving the gelatin at 45° C. to 60° C. to obtain a mixed solution.
[0074] In some embodiments, the mass ratio of modified cyclodextrin to gelatin can be 1:(5.67-99).
[0075] By adjusting the ratio of modified cyclodextrin to gelatin within the above range, a gel drug-carrying material with a suitable modified cyclodextrin content can be prepared, which is beneficial for the gel material to have a suitable drug sustained-release effect while having good mechanical strength. Within this range, by adjusting the mass ratio of modified cyclodextrin to gelatin, the drug loading amount and drug release rate of the gel drug-carrying material can be further regulated to meet the release rate requirements of different types of drugs.
[0076] S230, adding the mixed liquid into a mold, cooling and molding, and obtaining a prepolymer.
[0077] S240, mixing a crosslinking agent with a solvent to obtain a crosslinking agent solution, adding a prepolymer to the crosslinking agent solution, and allowing the crosslinking agent to initiate polymerization of the prepolymer to obtain a polymer.
[0078] In some embodiments, the cross-linking agent may include one or more of glutaraldehyde, 1-ethyl-(3-dimethylaminopropyl)carbodiimide, N-hydroxysuccinimide, oxidized dextran, epoxy polyethylene glycol, epoxy acrylic acid, acrylic anhydride, and polyethylene glycol diglycidyl ether.
[0079] The cross-linking agent can induce cross-linking polymerization of modified cyclodextrin and gelatin to form a cross-linked polymer, or the cross-linking agent can react with the active groups on cyclodextrin and / or gelatin to introduce cross-linkable groups, and form a cross-linked polymer by cross-linking reaction with gelatin or cyclodextrin through the cross-linkable groups. Further, the self-cross-linking of modified cyclodextrin or gelatin can be introduced by introducing cross-linkable groups into the modified cyclodextrin and / or gelatin by the cross-linking agent, thereby further improving the mechanical strength and drug sustained release effect of the gel drug-carrying material obtained by cross-linking polymerization.
[0080] In some embodiments, the solvent may include one or more of methanol, ethanol, acetonitrile, and tetrahydrofuran.
[0081] In some embodiments, the mass content of the crosslinking agent in the crosslinking agent solution can be 0.005 g / mL to 0.5 g / mL. Exemplarily, the mass content of the crosslinking agent in the crosslinking agent solution can be 0.005 g / mL, 0.006 g / mL, 0.007 g / mL, 0.008 g / mL, 0.009 g / mL, 0.01 g / mL, 0.02 g / mL, 0.03 g / mL, 0.04 g / mL, 0.05 g / mL, 0.06 g / mL, 0.07 g / mL, 0.08 g / mL, 0.09 g / mL, 0.10 g / mL, 0.20 g / mL, 0.30 g / mL, 0.40 g / mL, 0.50 g / mL, or a range consisting of any of the above numerical values.
[0082] In some embodiments, the mass ratio of the crosslinker to gelatin can be 1:(0.01-0.1), optionally 1:(0.02-0.08), and more optionally 1:(0.04-0.7). The amount of the crosslinker is significantly excessive compared to gelatin. On the one hand, crosslinkable groups can be introduced into gelatin and / or modified cyclodextrin to initiate crosslinking polymerization of crosslinked modified cyclodextrin and gelatin; on the other hand, self-crosslinking of gelatin and / or modified cyclodextrin can be initiated, further improving the mechanical properties and sustained release properties of the drug-loaded gel material after polymerization.
[0083] In the embodiment of the present application, the mixture of gelatin and modified cyclodextrin is first formed in a mold and then cross-linked and polymerized. After the cross-linking agent is added, the small molecules of the cross-linking agent can enter the pore structure of the prepolymer to initiate the polymerization of the prepolymer. The method of forming first and then polymerizing can avoid the problem of difficult forming caused by the difficulty in dissolving and dispersing gelatin and modified cyclodextrin polymers, and improve the stability of the structural characteristics of the gel drug-carrying material after forming.
[0084] S250, washing the polymer with purified water and drying to obtain a gel drug-loaded material.
[0085] In some embodiments, the washing time can be 0.5 days to 14 days, optionally 1 day to 7 days, and more optionally 3 days.
[0086] In some embodiments, the drying may be forced air drying, and the drying temperature may be 20°C to 30°C, optionally 22°C to 28°C, and more optionally 25°C.
[0087] In some embodiments, the drying time may be 0.5 h to 24 h, optionally 5 h to 23 h, and more optionally 10 h to 22 h.
[0088] According to the embodiments of the present application, the preparation method provided in the embodiments of the second aspect of the present application can be used to prepare the gel drug-loaded material of the embodiments of the first aspect of the present application.
[0089] The embodiments of the third aspect of the present application provide the use of the gel drug-loaded material according to the embodiments of the first aspect of the present application or the gel drug-loaded material obtained by the preparation method according to the embodiments of the second aspect of the present application in a drug-loaded sustained-release system.
[0090] Drug sustained release system
[0091] An embodiment of the fourth aspect of the present application provides a drug-loaded sustained-release system, which includes a drug-loaded matrix and a drug loaded on the drug-loaded matrix, wherein the drug-loaded matrix includes a gel drug-loaded material according to an embodiment of the first aspect of the present application or a gel drug-loaded material obtained by the preparation method of an embodiment of the second aspect of the present application.
[0092] In some embodiments, the drug loading amount of the drug-loaded sustained-release system is 700 μg / mg to 1000 μg / mg.
[0093] In some embodiments, the drug includes one or more of an anti-proliferative drug, an ocular hypotensive drug, an anti-inflammatory drug, an antibacterial drug, an anti-allergic drug, and an ocular lubricating drug.
[0094] Illustratively, the antiproliferative drug may include one or more of heparin, mitomycin, methotrexate, fluorouracil, cytarabine, paclitaxel, vincristine, doxorubicin, etoposide, anastrozole, bortezomib, and bleomycin.
[0095] The intraocular pressure-lowering drugs may include one or more of paclitaxel, carteolol, pilocarpine, and dipivefrin.
[0096] Anti-inflammatory drugs may include one or more of chloramphenicol, flumethasone ophthalmicus, dexamethasone, moxifloxacin, acyclovir, and tobramycin.
[0097] Anti-allergic drugs may include one or more of olopatadine, azelastine, sodium cromoglycate, ketotifen, antalol, ketorolac, nedocromil, and emedastine.
[0098] The ocular lubricating drug may include one or more of sodium hyaluronate, polyethylene glycol, polyvinyl alcohol, and propylene glycol.
[0099] In some embodiments, the drug-loaded sustained-release system can be one or more of an ocular drainage tube, a sustained-release drug delivery plug, and a sustained-release corneal contact lens.
[0100] Example
[0101] Some specific examples of drug-carrying materials provided by the present application are given below. The embodiments described below are exemplary and are only used to explain the present application, and should not be construed as limiting the present application. If no specific techniques or conditions are specified in the embodiments, the techniques or conditions described in the literature in the art or the product instructions are used. The reagents or instruments used without specifying the manufacturer are all conventional products that can be obtained commercially.
[0102] Example 1
[0103] Preparation of gel drug-loaded materials
[0104] 0.2 g of 3A-amino-3A-deoxy-(2AS,3AS)-β-cyclodextrin was added to 8 mL of PBS solution, stirred to fully dissolve, 2 g of type A pigskin gelatin was added, heated at 50°C to dissolve and stirred to mix evenly, allowed to stand for degassing, and then injected into a mold at 50°C, and slowly cooled to 4°C to form a plurality of tubular prepolymers;
[0105] The tubular prepolymer was placed in 50 mL of 0.01 g / mL glutaraldehyde methanol solution, placed on a shaking table, set the temperature to 25° C., shaken for reaction for 20 h, taken out and dried at room temperature to obtain a drainage tube made of a gel drug-loaded material.
[0106] Preparation of drug-loaded drainage tube
[0107] 10 mg of mitomycin was added to 5 mL of normal saline to prepare a 2 mL / mL mitomycin solution. The drainage tube was immersed in the mitomycin solution and mixed by shaking at 25°C for 20 hours. The drainage tube was taken out and the residual mitomycin on the surface was washed with deionized water. The tube was dried at 25°C to obtain a drug-loaded drainage tube.
[0108] Example 2
[0109] The difference from Example 1 is that an equal amount of 6-perdeoxy-6-per(2-carboxyethyl)-γ-cyclodextrin is used instead of 3A-amino-3A-deoxy-(2AS,3AS)-β-cyclodextrin, and 0.2 g of polyethylene glycol diglycidyl ether (cross-linking agent) is added, and the rest is the same as Example 1.
[0110] Example 3
[0111] The difference from Example 1 is that an equal amount of mono-(6-aldehyde-6-deoxy)-β-cyclodextrin is used to replace 3A-amino-3A-deoxy-(2AS, 3AS)-β-cyclodextrin, and the rest is the same as Example 1.
[0112] Example 4
[0113] The difference from Example 1 is that the amount of modified cyclodextrin is 0.02 g, the amount of gelatin is 2.18 g, and the rest is the same as Example 1.
[0114] Example 5
[0115] The difference from Example 1 is that the amount of modified cyclodextrin is 0.33 g, the amount of gelatin is 1.87 g, and the rest is the same as Example 1.
[0116] Example 6
[0117] The difference from Example 1 is that the amount of modified cyclodextrin is 1 g, the amount of gelatin is 1.2 g, and the rest is the same as Example 1.
[0118] Example 7
[0119] 0.2 g of 3A-amino-3A-deoxy-(2AS,3AS)-β-cyclodextrin was added to 8 ml of PBS solution, 10 mg of latanoprost was added, and 2 g of type A pig skin gelatin was added after sufficient stirring, and the mixture was heated at 50°C to dissolve and stir evenly, and the mixture was degassed at rest, and the gelatin solution was injected into the mold while maintaining the temperature at 50°C, and slowly cooled to 4°C to prepare a plurality of block materials, and the molded embolization material was taken out for use;
[0120] The formed embolic material was added to a 1 mol / L 2-(N-morpholinyl)ethanesulfonic acid solution containing 20 mg 1-ethyl-(3-dimethylaminopropyl)carbodiimide and 20 mg N-hydroxysuccinimide, and placed in a shaking shaker at 25°C for 20 hours. The embolic material was taken out and dried at room temperature to obtain a drug-loaded embolic material.
[0121] Comparative Example 1
[0122] Preparation of drug-loaded materials
[0123] Add 2g of type A pig skin gelatin into 8ml of PBS solution, heat at 50℃ to dissolve and stir to mix evenly, let it stand to degas, maintain the temperature at 50℃, inject the gelatin solution into the mold, slowly cool to 4℃ to prepare multiple tubular materials, take out the molded materials and set aside.
[0124] The tubular prepolymer was placed in 50 mL of 0.01 g / mL glutaraldehyde methanol solution, placed on a shaking table, set the temperature to 25° C., shaken for reaction for 20 h, taken out and dried at room temperature to obtain a drainage tube made of a gel drug-loaded material.
[0125] Preparation of drug-loaded drainage tube
[0126] 10 mg of mitomycin was added to 5 mL of normal saline to prepare a 2 mL / mL mitomycin solution. The drainage tube was immersed in the mitomycin solution and mixed by shaking at 25°C for 20 hours. The drainage tube was taken out and the residual mitomycin on the surface was washed with deionized water. The tube was dried at 25°C to obtain a drug-loaded drainage tube.
[0127] Test Section
[0128] The drainage tube or embolizer prepared above is tested according to the following items:
[0129] 1. Drug loading detection
[0130] Place a blank drainage tube or embolizer in a buffer solution preloaded with drugs at a certain concentration and soak for 2-72 hours. Use high performance liquid chromatography to detect the drug residue in the drug buffer solution. Subtract the total amount of drug in the drug buffer solution before embedding from the drug residue in the drug buffer solution after embedding to calculate the drug loading in the drainage tube or embolizer. The results are shown in Table 1.
[0131] 2. Drug sustained release effect
[0132] The drainage tube or embolizer after drug loading was placed in a test fixture containing balanced salt solution (BBS), the temperature was controlled at 37°C, the flow rate was set to 5ul / min, and the time points of 0, 2 days, 3 days, 5 days, 10 days, 15 days, 20 days, 25 days, and 30 days were set. The BBS solution after outflow was taken respectively, and the drug content in the solution was detected by high performance liquid chromatography. The drug sustained release rate was calculated by the ratio of drug content to release time. The results are shown in Table 1.
[0133] 3. Mechanical strength
[0134] The drainage tube or embolizer block was kept at a temperature of 37°C and a shear strain of 0.1%, and the corresponding storage modulus was measured using a rheometer. The results are shown in Table 1.
[0135] 4. Anti-scarring experiment
[0136] L929 mouse fibroblasts were inoculated into 12-well culture plates and placed in an incubator until the confluence reached 80-90%. The drug-loaded and sterilized drainage tube was fixed on the 12-well culture plates after incubation. The culture plates were placed in a CO2 incubator and incubated at 37°C and 5% CO2 for 24-72 hours. The cell number and morphological changes were observed under a microscope. The results were referred to Figure 3 .
[0137] Table 1
[0138] Drug loading (μg / mg) Drug sustained release rate (μg / h) Storage modulus (Pa) Example 1 850 1.3 <![CDATA[2.63x10 6 ]]> Example 2 830 1.3 <![CDATA[3.09x10 6 ]]> Example 3 810 1.1 <![CDATA[2.65x10 6 ]]> Example 4 760 1.8 <![CDATA[2.91x10 6 ]]> Example 5 900 1.9 <![CDATA[1.31x10 6 ]]> Example 6 950 2.1 <![CDATA[1.35x10 5 ]]> Example 7 1000 1.4 <![CDATA[1.15x10 5 <!-- 8 -->]]> Comparative Example 1 700 5.4 <![CDATA[3.01x10 6 ]]>
[0139] Combined with the data in Table 1, it can be seen that compared with gelatin itself, the modified cyclodextrin can have a higher drug loading capacity after cross-linking with gelatin. Figure 2 From the drug release curve in FIG. 1 , it can be seen that the gel drug-carrying material provided in the embodiment of the present application can have a lower drug release rate.
[0140] Figure 3 The anti-scar test results of the drainage tube in Example 1 of the present application are shown in the figure, wherein A and B are respectively the initial coating state of cell culture and the state after 3 days of cell culture in the drainage tube in Example 1 without drug loading; C and D are respectively the initial coating state of cell culture and the state after 3 days of cell culture in the drainage tube in Example 1 under drug loading. It can be seen that the drainage tube made of the gel drug loading material provided in the example of the present application has a significant effect of inhibiting cell proliferation after drug loading, and can achieve a better anti-scarring effect.
[0141] Although the present application has been described with reference to preferred embodiments, various modifications may be made thereto and parts thereof may be replaced with equivalents without departing from the scope of the present application. In particular, the various technical features mentioned in the various embodiments may be combined in any manner as long as there are no structural conflicts. The present application is not limited to the specific embodiments disclosed herein, but includes all technical solutions falling within the scope of the claims.
Claims
1. A gel drug-carrying material, characterized in that: The gel drug-carrying material comprises a cross-linked polymer of gelatin and modified cyclodextrin, wherein the gelatin and the modified cyclodextrin are cross-linked and polymerized via a cross-linking group, wherein the cross-linking group comprises one or more of an amide group, an imine group, an ester group and an ether group.
2. The drug-carrying gel material according to claim 1, characterized in that: The modified groups of the modified cyclodextrin include one or more of amino, carboxyl and aldehyde groups.
3. The drug-carrying gel material according to claim 2, characterized in that: The content of the modified group in the modified cyclodextrin is 0.88 mmol / g to 4.40 mmol / g.
4. The drug-carrying gel material according to claim 2 or 3, characterized in that: The modified cyclodextrin includes one or more of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and their respective derivatives modified by a modifying group.
5. The drug-carrying gel material according to claim 4, characterized in that: The modified cyclodextrin includes one or more of mono-(6-amino-6-deoxy)-β-cyclodextrin, 3A-amino-3A-deoxy-(2AS, 3AS)-β-cyclodextrin, 6-perdeoxy-6-per(2-carboxyethyl)-γ-cyclodextrin, and mono-(6-aldehyde-6-deoxy)-β-cyclodextrin.
6. The drug-carrying gel material according to any one of claims 1 to 5, characterized in that: The mass content of modified cyclodextrin in the gel drug-carrying material is 1% to 15%.
7. The drug-carrying gel material according to claim 1, characterized in that: The gel drug-carrying material has a porous structure with a porosity of 50% to 70%.
8. A method for preparing a gel drug-carrying material, characterized in that: The steps include: Modified cyclodextrin and gelatin are provided separately; The modified cyclodextrin and the gelatin are cross-linked and polymerized via a cross-linking group to obtain the gel drug-carrying material, wherein the cross-linking group includes one or more of an amide group, an imine group, an ester group and an ether group.
9. The preparation method according to claim 8, characterized in that: The step of cross-linking the modified cyclodextrin and the gelatin via a cross-linking group comprises: The modified cyclodextrin is mixed with gelatin and molded to obtain a prepolymer; The prepolymer is mixed with a cross-linking agent to initiate polymerization of the prepolymer to obtain the gel drug-carrying material.
10. The preparation method according to claim 9, characterized in that: The step of mixing and molding the modified cyclodextrin with gelatin to obtain a prepolymer comprises: dispersing the modified cyclodextrin in a dispersant to obtain a modified cyclodextrin dispersion; adding the gelatin into the cyclodextrin dispersion to mix the modified cyclodextrin with the gelatin to obtain a mixed solution; The mixed liquid is molded in a mold to obtain the prepolymer.
11. The preparation method according to claim 10, characterized in that: The preparation method satisfies at least one of the following conditions: (1) The dispersant includes one or both of PBS solution and deionized water; (2) The mass content of modified cyclodextrin in the dispersion is 0.25 g / mL to 2.5 g / mL; (3) The mass ratio of the modified cyclodextrin to the gelatin is 1:(5.67-99); (4) The mixing temperature of the modified cyclodextrin and the gelatin is 45°C to 60°C.
12. The preparation method according to claim 9, characterized in that: The step of mixing the prepolymer with a cross-linking agent to initiate polymerization of the prepolymer to obtain the gel drug-carrying material comprises: mixing the cross-linking agent with a solvent to obtain a cross-linking agent solution; adding the prepolymer into the crosslinking agent solution, so that the crosslinking agent initiates the polymerization of the prepolymer to obtain a polymer; The polymer is washed with water and then dried to obtain the gel drug-carrying material.
13. The preparation method according to claim 12, characterized in that: The preparation method satisfies at least one of the following conditions: (1) The cross-linking agent includes one or more of glutaraldehyde, 1-ethyl-(3-dimethylaminopropyl)carbodiimide, N-hydroxysuccinimide, oxidized dextran, epoxy polyethylene glycol, epoxy acrylic acid, acrylic anhydride, and polyethylene glycol diglycidyl ether; (2) The solvent includes one or more of methanol, ethanol, acetonitrile, and tetrahydrofuran; (3) The mass content of the crosslinking agent in the crosslinking agent solution is 0.005 g / mL to 0.5 g / mL; (4) The mass ratio of the cross-linking agent to the gelatin is 1:(0.01-0.1).
14. The preparation method according to claim 8, characterized in that: The modified cyclodextrin includes cyclodextrin loaded with drugs.
15. Use of the drug-carrying gel material according to any one of claims 1 to 7 or the drug-carrying gel material obtained by the preparation method according to any one of claims 8 to 16 in preparing a drug-carrying sustained-release system.
16. A drug-loaded sustained-release system, characterized in that: The invention comprises a drug-carrying matrix and a drug loaded on the drug-carrying matrix, wherein the drug-carrying matrix comprises a gel drug-carrying material according to any one of claims 1 to 6 or a gel drug-carrying material obtained by a preparation method according to any one of claims 7 to 14, and the gel drug-carrying material is loaded with a drug.
17. The drug-loaded sustained-release system according to claim 16, characterized in that: The drug loading amount of the drug-loaded sustained-release system is 700 μg / mg to 1000 μg / mg.
18. The drug-loaded sustained-release system according to claim 16, characterized in that: The drugs include one or more of anti-proliferative drugs, intraocular pressure-lowering drugs, anti-inflammatory drugs, antibacterial drugs, anti-allergic drugs, and eye lubricating drugs.
19. The drug-loaded sustained-release system according to any one of claims 16 to 18, characterized in that: The drug-loaded sustained-release system includes one or more of an eye drainage tube, a sustained-release drug delivery plug, and a sustained-release corneal contact lens.
